IL2 and cancer: Before evaluating WNK3 and SIK3, we first confirmed that H460 and H2009 cells stably expressing shPD-L1 (Supplementary Fig. 2a, c) exhibited increased susceptibility (decreased cancer cell viability) to IL-2 and anti-CD3-activated peripheral blood mononuclear cells (PBMCs; Supplementary Fig. 2b, d).